Wendy Painter - Search Results

Year	Number of Results
2010	2
2011	2
2012	3
2021	7
2022	2

1

Molnupiravir, an Oral Antiviral Treatment for COVID-19.

Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P, Lipansky F, Painter WP. Fischer W, et al. Among authors: painter wp. medRxiv. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639. Preprint. medRxiv. 2021. PMID: 34159342 Free PMC article. Updated.

2

Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.

Painter GR, Natchus MG, Cohen O, Holman W, Painter WP. Painter GR, et al. Among authors: painter wp. Curr Opin Virol. 2021 Oct;50:17-22. doi: 10.1016/j.coviro.2021.06.003. Epub 2021 Jun 18. Curr Opin Virol. 2021. PMID: 34271264 Free PMC article. Review.

3

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.

Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR. Painter WP, et al. Antimicrob Agents Chemother. 2021 Mar 1;65(5):e02428-20. doi: 10.1128/AAC.02428-20. Online ahead of print. Antimicrob Agents Chemother. 2021. PMID: 33649113 Free PMC article.

4

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.

Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T, Lyon R, Downs N, Walker L, Tansley-Hancock O, Greenhalf W, Woods C, Reynolds H, Marwood E, Mozgunov P, Adams E, Bullock K, Holman W, Bula MD, Gibney JL, Saunders G, Corkhill A, Hale C, Thorne K, Chiong J, Condie S, Pertinez H, Painter W, Wrixon E, Johnson L, Yeats S, Mallard K, Radford M, Fines K, Shaw V, Owen A, Lalloo DG, Jacobs M, Griffiths G. Khoo SH, et al. Among authors: painter w. J Antimicrob Chemother. 2021 Nov 12;76(12):3286-3295. doi: 10.1093/jac/dkab318. J Antimicrob Chemother. 2021. PMID: 34450619 Free PMC article. Clinical Trial.

5

Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.

Holman W, Holman W, McIntosh S, Painter W, Painter G, Bush J, Cohen O. Holman W, et al. Among authors: painter w. Trials. 2021 Aug 23;22(1):561. doi: 10.1186/s13063-021-05538-5. Trials. 2021. PMID: 34425873 Free PMC article. Clinical Trial.

6

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.

Fischer WA 2nd, Eron JJ Jr, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Coombs RW, James Loftis A, Alabanza P, Lipansky F, Painter WP. Fischer WA 2nd, et al. Among authors: painter wp. Sci Transl Med. 2022 Jan 19;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430. Epub 2022 Jan 19. Sci Transl Med. 2022. PMID: 34941423 Clinical Trial.

7

Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates.

Mollan KR, Eron JJ, Krajewski TJ, Painter W, Duke ER, Morse CG, Goecker EA, Premkumar L, Wolfe CR, Szewczyk LJ, Alabanza PL, Loftis AJ, Degli-Angeli EJ, Brown AJ, Dragavon JA, Won JJ, Keys J, Hudgens MG, Fang L, Wohl DA, Cohen MS, Baric RS, Coombs RW, Sheahan TP, Fischer WA 2nd. Mollan KR, et al. Among authors: painter w. medRxiv. 2021 Jun 25:2021.05.28.21258011. doi: 10.1101/2021.05.28.21258011. Preprint. medRxiv. 2021. PMID: 34100024 Free PMC article. Updated.

8

Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates.

Mollan KR, Eron JJ, Krajewski TJ, Painter W, Duke ER, Morse CG, Goecker EA, Premkumar L, Wolfe CR, Szewczyk LJ, Alabanza PL, Loftis AJ, Degli-Angeli EJ, Brown AJ, Dragavon JA, Won JJ, Keys J, Hudgens MG, Fang L, Wohl DA, Cohen MS, Baric RS, Coombs RW, Sheahan TP, Fischer WA. Mollan KR, et al. Among authors: painter w. Clin Infect Dis. 2021 Nov 23:ciab968. doi: 10.1093/cid/ciab968. Online ahead of print. Clin Infect Dis. 2021. PMID: 35022711

9

Development of CMX001 for the Treatment of Poxvirus Infections.

Lanier R, Trost L, Tippin T, Lampert B, Robertson A, Foster S, Rose M, Painter W, O'Mahony R, Almond M, Painter G. Lanier R, et al. Among authors: painter w. Viruses. 2010 Dec;2(12):2740-2762. doi: 10.3390/v2122740. Viruses. 2010. PMID: 21499452 Free PMC article.

10

Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.

Lederman ER, Davidson W, Groff HL, Smith SK, Warkentien T, Li Y, Wilkins KA, Karem KL, Akondy RS, Ahmed R, Frace M, Shieh WJ, Zaki S, Hruby DE, Painter WP, Bergman KL, Cohen JI, Damon IK. Lederman ER, et al. Among authors: painter wp. J Infect Dis. 2012 Nov;206(9):1372-85. doi: 10.1093/infdis/jis510. Epub 2012 Aug 16. J Infect Dis. 2012. PMID: 22904336 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results